华神科技(000790) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was CNY 189,396,652.78, a decrease of 4.97% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 6,298,808.39, down 26.47% year-on-year[5]. - The basic earnings per share (EPS) was CNY 0.0100, reflecting a decline of 27.01% compared to the previous year[5]. - Total operating revenue for the current period reached ¥672,455,495.51, an increase of 10.83% from ¥606,692,403.34 in the previous period[27]. - Total operating costs amounted to ¥651,127,262.01, up 13.36% from ¥574,557,078.03 in the prior period[27]. - Net profit for the current period was ¥23,045,825.19, compared to ¥22,599,592.44 in the previous period, reflecting a growth of 1.97%[28]. - The company’s total profit for the current period was ¥25,131,544.82, down from ¥27,740,788.27 in the previous period, a decrease of 9.36%[28]. Assets and Liabilities - Total assets increased by 26.00% to CNY 2,113,117,786.32 compared to the end of the previous year[5]. - As of September 30, 2023, total assets reached CNY 2,113,117,786.32, an increase from CNY 1,677,058,446.16 at the beginning of the year, representing a growth of approximately 26%[24]. - Current assets totaled CNY 1,033,644,456.04, up from CNY 784,306,279.15 at the start of the year, indicating a growth of about 32%[24]. - Total liabilities amounted to CNY 1,040,513,645.63, up from CNY 671,561,352.92, which is an increase of approximately 55%[25]. - The company's equity attributable to shareholders reached CNY 1,029,637,024.24, compared to CNY 1,003,077,682.29 at the beginning of the year, showing a growth of about 2.66%[25]. Cash Flow - Cash flow from operating activities showed a net outflow of CNY 27,098,105.60, a significant decrease of 150.49%[5]. - Cash received from sales of goods and services was ¥598,365,400.52, an increase from ¥579,893,910.49 in the previous period[29]. - The net cash inflow from financing activities was CNY 183,155,790.73, compared to CNY 112,587,254.38 in the previous year, representing an increase of approximately 62.7%[30]. - Total cash and cash equivalents at the end of the period amounted to CNY 82,725,147.76, up from CNY 37,877,616.26 at the beginning of the period, indicating a net increase of CNY 44,847,531.50[30]. - Cash received from borrowings was CNY 340,875,000.00, significantly higher than CNY 200,000,000.00 in the same period last year, reflecting a growth of 70.4%[30]. - Cash outflows for debt repayment totaled CNY 109,796,556.99, compared to CNY 43,114,000.00 in the previous year, marking an increase of 154.1%[30]. Investments and Acquisitions - The company acquired 51% of Tibet Kangyu Pharmaceutical Co., Ltd. for CNY 51 million, enhancing its strategic position in the pharmaceutical industry[18]. - The acquisition aims to strengthen the company's pharmaceutical supply chain and improve its market resilience and profitability[19]. - The company plans to issue shares to acquire 100% of Sichuan Bohao Biotechnology Co., Ltd. for CNY 792.5754 million, pending shareholder and regulatory approvals[20]. - The share issuance for the acquisition is priced at CNY 3.9 per share, with a total of 203,224,472 shares to be issued[20]. - The company has made substantial investments in fixed assets, which increased to CNY 360,035,347.06 from CNY 319,654,176.55, reflecting a growth of about 12.6%[24]. Governance and Management - The company completed the election of a new board of directors and supervisory board on July 27, 2023, enhancing governance structure[22]. - The company is actively pursuing asset acquisition and fundraising initiatives, as detailed in multiple announcements throughout 2023[21]. - The company's management indicated a focus on cost control and efficiency improvements in future operations[27]. Other Financial Metrics - Financial expenses surged by 513.61% to CNY 11,187,194.57, mainly due to increased financing costs[12]. - The company recognized government subsidies amounting to CNY 5,705,397.81, a 304.48% increase year-on-year[12]. - The goodwill increased by 100.74% to CNY 112,537,740.45, attributed to the acquisition of a subsidiary[10]. - The minority shareholders' equity rose dramatically by 1675.93% to CNY 42,967,116.45, reflecting the consolidation of new entities[10]. - Operating cash inflow from government subsidies increased by 37.80% to CNY 28,371,719.98 in the first nine months of 2023 compared to CNY 20,589,513.90 in the same period of 2022[13]. - Tax payments rose by 38.11% to CNY 57,765,580.98 due to increased revenue in the current period[13]. - Capital expenditures on fixed and intangible assets decreased by 54.07% to CNY 65,648,219.69, primarily due to reduced long-term asset purchases[13]. - Cash paid for investments dropped by 72.40% to CNY 15,400,000.00, reflecting a decrease in investment projects[13]. Reporting and Compliance - The company did not undergo an audit for the third quarter report[31]. - The report was released on October 31, 2023, and is the first to apply the new accounting standards[31].